Skip to main content
. Author manuscript; available in PMC: 2008 Nov 25.
Published in final edited form as: Eur J Neurosci. 2003 Apr;17(8):1607–1616. doi: 10.1046/j.1460-9568.2003.02597.x

Fig. 3.

Fig. 3

Zolpidem augmented mIPSCs in control, but not epileptic, DGCs. (A1) Averaged mIPSCs (50 events) taken before (thin line) and during (thick line) bath application of ZOL (200 nM) to a control DGC. (B1) Cumulative probability–conductance and (C1) cumulative probability –50% decay time (T50) plots for the same cell as represented in A1, demonstrating that ZOL significantly augmented mIPSC T50 in control DGCs. (A2) Averaged mIPSCs taken before (thin line) and during (thick line) bath application of ZOL to epileptic DGCs, demonstrating no effect on mIPSC amplitude or T50 (see A2 lower sweep; note difference in scale bar amplitude). (B2 and C2) Cumulative probability–conductance and –T50 plots, demonstrating no effect of ZOL on mIPSC conductance or T50.